Isolated CYP19A1 nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as well as CYP19A1 allozymes. Methods for determining the aromatase status of an individual also are provided, as are methods for determining if a subject is predisposed to certain clinical conditions.